DAYANA DEL CARMEN MAITA CORONEL MD
Prescription History 1447697693
Internal Medicine - Infectious Disease in Sioux Falls, SD

NPI Status: Active since May 29, 2013

Contact Information

6709 S MINNESOTA AVE STE 102
SIOUX FALLS, SD
ZIP 57108
Phone: (605) 322-7250
Fax: (605) 322-7251

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DAYANA DEL CARMEN MAITA CORONEL MD, an active Infectious Disease specialist practicing in Sioux Falls, SD. Our medical registry currently tracks 11 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 219 documented patient claims. Among these therapy options, the most frequently utilized medication is Cefadroxil, which accounts for 49 claims alone.


Amoxicillin-Clavulanate Potass

Generic Formulation: Amoxicillin/Potassium ClavSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 28
30-Day Fills 28.6
Days Supply 778
SD State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills20.1
Peer Average Days Supply191
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 47.4% more claims than the standard regional baseline profile for SD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $949.25 across this reporting matrix range.

Provider Avg Cost Per Claim

$33.90

State Avg Cost Per Claim

$13.15

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A fixed-ratio combination of amoxicillin trihydrate and potassium clavulanate.

Therapeutic Applications

Amoxicillin/clavulanic acid is a combination penicillin-type antibiotic used to treat a wide variety of bacterial infections. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Azithromycin

Generic Formulation: AzithromycinSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 11
30-Day Fills 16.4
Days Supply 406
SD State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills30.1
Peer Average Days Supply340
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 59.3% less volume than the regional standard for practitioners inside SD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $63.68 across this reporting matrix range.

Provider Avg Cost Per Claim

$5.79

State Avg Cost Per Claim

$10.33

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.

Therapeutic Applications

This medication is used to treat certain eye infections. It is a macrolide antibiotic that works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Biktarvy

Generic Formulation: Bictegrav/Emtricit/Tenofov AlaSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
SD State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills36.1
Peer Average Days Supply1,082
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 66.7% less volume than the regional standard for practitioners inside SD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $43,967.11 across this reporting matrix range.

Provider Avg Cost Per Claim

$3,663.93

State Avg Cost Per Claim

$3,819.58

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination product is used by itself to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This product is a combination of 3 different drugs: bictegravir, emtricitabine, and tenofovir alafenamide. Bictegravir is called an integrase strand transfer inhibitor-INSTI. Emtricitabine is called a nucleoside reverse transcriptase inhibitor, while tenofovir alafenamide is called a nucleotide reverse transcriptase inhibitor. Emtricitabine and tenofovir alafenamide are often called NRTIs. Bictegravir/emtricitabine/tenofovir alafenamide is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Cefadroxil

Generic Formulation: CefadroxilSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 49
30-Day Fills 70.0
Days Supply 1,967
SD State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills33.9
Peer Average Days Supply529
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 63.3% higher than the standard regional baseline profile for SD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,947.02 across this reporting matrix range.

Provider Avg Cost Per Claim

$60.14

State Avg Cost Per Claim

$16.09

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Long-acting, broad-spectrum, water-soluble, CEPHALEXIN derivative.

Therapeutic Applications

This medication is used to treat a wide variety of bacterial infections. It belongs to a class of drugs known as cephalosporin antibiotics. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Ciprofloxacin Hcl

Generic Formulation: Ciprofloxacin HclSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 23
30-Day Fills 25.3
Days Supply 669
SD State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills23.0
Peer Average Days Supply199
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across SD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $321.50 across this reporting matrix range.

Provider Avg Cost Per Claim

$13.98

State Avg Cost Per Claim

$7.13

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A broad-spectrum antimicrobial carboxyfluoroquinoline.

Therapeutic Applications

This medication is used to treat eye infections. Ciprofloxacin belongs to a class of drugs called quinolone antibiotics. It works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or overuse of any antibiotic can lead to its decreased effectiveness.

Doxycycline Hyclate

Generic Formulation: Doxycycline HyclateSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 33
30-Day Fills 35.0
Days Supply 892
SD State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills26.2
Peer Average Days Supply423
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 43.5% more claims than the standard regional baseline profile for SD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $967.00 across this reporting matrix range.

Provider Avg Cost Per Claim

$29.30

State Avg Cost Per Claim

$27.16

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic tetracycline derivative with similar antimicrobial activity.

Therapeutic Applications

This medication is used to treat a wide variety of bacterial infections, including those that cause acne. This medication is also used to prevent malaria. This medication is known as a tetracycline antibiotic. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Fluconazole

Generic Formulation: FluconazoleSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 15
30-Day Fills 17.4
Days Supply 518
SD State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills20.8
Peer Average Days Supply264
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across SD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $931.82 across this reporting matrix range.

Provider Avg Cost Per Claim

$62.12

State Avg Cost Per Claim

$18.69

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.

Therapeutic Applications

Fluconazole is used to treat vaginal yeast infections. It works by stopping the growth of common types of vaginal yeast (fungus). This medication belongs to a class of drugs called azole antifungals.

Genvoya

Generic Formulation: Elviteg/Cob/Emtri/Tenof AlafenSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 390
SD State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills20.6
Peer Average Days Supply617
Conservative Utilization

This provider writes prescriptions for this formulation 35.0% less frequently than the standard regional baseline metric for practitioners inside SD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $52,367.51 across this reporting matrix range.

Provider Avg Cost Per Claim

$4,028.27

State Avg Cost Per Claim

$3,810.37

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of the ANTI-HIV AGENTS elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate that is used in the treatment of HIV INFECTIONS.

Therapeutic Applications

This product is used to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This product contains 4 different medications: elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide. Elvitegravir is known as an integrase inhibitor. Cobicistat helps elvitegravir work better. Emtricitabine is called a nucleoside reverse transcriptase inhibitor, while tenofovir alafenamide is called a nucleotide reverse transcriptase inhibitor; both kinds of drugs are often called NRTIs. Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Isentress

Generic Formulation: Raltegravir PotassiumSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
SD State Average Benchmarks
Peer Average Claims12.0
Peer Average 30-Day Fills12.0
Peer Average Days Supply360
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across SD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $19,932.62 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,812.06

State Avg Cost Per Claim

$1,847.98

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pyrrolidinone derivative and HIV INTEGRASE INHIBITOR that is used in combination with other ANTI-HIV AGENTS for the treatment of HIV INFECTION.

Therapeutic Applications

Raltegravir is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Raltegravir is known as an integrase inhibitor. It blocks the virus from growing and infecting more cells. Raltegravir is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Minocycline Hcl

Generic Formulation: Minocycline HclSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 11
30-Day Fills 17.0
Days Supply 495
SD State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills27.9
Peer Average Days Supply776
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 52.2% less volume than the regional standard for practitioners inside SD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $859.31 across this reporting matrix range.

Provider Avg Cost Per Claim

$78.12

State Avg Cost Per Claim

$35.04

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections.

Therapeutic Applications

This medication is used to treat acne or rosacea. Minocycline belongs to a class of drugs known as tetracycline antibiotics. However, it is not used to treat skin infections. It helps decrease pimples and red bumps that happen with acne or rosacea.

Sulfamethoxazole-Trimethoprim

Generic Formulation: Sulfamethoxazole/TrimethoprimSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 13
30-Day Fills 25.0
Days Supply 705
SD State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills23.3
Peer Average Days Supply329
Conservative Utilization

This provider writes prescriptions for this formulation 38.1% less frequently than the standard regional baseline metric for practitioners inside SD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $198.96 across this reporting matrix range.

Provider Avg Cost Per Claim

$15.30

State Avg Cost Per Claim

$5.48

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.

Therapeutic Applications

This medication is a combination of two antibiotics: sulfamethoxazole and trimethoprim. It is used to treat a wide variety of bacterial infections (such as middle ear, urine, respiratory, and intestinal infections). It is also used to prevent and treat a certain type of pneumonia (pneumocystis-type). This medication should not be used by children less than 2 months of age due to the risk of serious side effects. This medication treats only certain types of infections. It will not work for viral infections (such as flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DAYANA DEL CARMEN MAITA CORONEL MD provides transparency into local medical care patterns within Sioux Falls, SD.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Infectious Disease** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.